Drug Combination Details
| General Information of the Combination (ID: C00331) | |||||
|---|---|---|---|---|---|
| Name | Quercetin NP Info | + | Temozolomide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Melanoma
[ICD-11: 2C30]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-MEL-28 | CVCL_0526 | Cutaneous melanoma | Homo sapiens | ||
| SK-MEL-5 | CVCL_0527 | Cutaneous melanoma | Homo sapiens | |||
| DB-1 | Melanoma | Homo sapiens | ||||
| Experimental
Result(s) |
Qct can sensitize cells to TMZ and that the mechanisms of sensitization involve modulation of p53 family members. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer. 2010 Jun 11;10:282. | |||
